CHEK1 and neoplasm: Other combination partner for ICI includes the CHK1 inhibitor prexasertib (LY2606368), which potently activated the STING/TBK1/IRF3 innate immune pathway and upregulated tumor expression of PD‐L1, suggesting its synergistical potential with ICIs.436, 437